Tandem Diabetes Care (NasdaqGM:TNDM) FY Conference Transcript

Tandem Diabetes Care FY Conference Summary Company Overview - Company: Tandem Diabetes Care (NasdaqGM:TNDM) - Date of Conference: March 04, 2026 Key Points Industry and Market Dynamics - The diabetes care market has evolved, with a shift from simple device outcomes to include market access and form factor as competitive elements [5][6] - The introduction of new competitive devices has changed the basis of competition in the industry [5] Strategic Initiatives - 2024 Strategy: Focus on monetization of the sales force, innovative products, and market access through the pharmacy channel [6] - Sales Force Expansion: Increased sales force productivity through new models and a new CRM system [6][7] - Direct Market Access: Initiated direct sales in three new countries in 2025, with plans to expand to three more in 2027 [7][8] Product Innovations - Control-IQ+: Launched in 2025, designed to be user-friendly and competitive in the market [8] - FreeStyle Libre 3 Integration: Enhanced compatibility with t:slim, targeting the 60% of U.S. users on iOS [9] - Mobi Development: Ongoing enhancements to Mobi, with Android compatibility added [9] Pharmacy Channel Strategy - PAYGO Model: Transitioning to a pay-as-you-go model, expected to double reimbursement over a four-year product life [14][19] - Market Positioning: Anticipated monthly cost of $350 per patient under PAYGO, compared to $83 through traditional DME [21][22] - Competitive Advantage: Established install base allows for quicker conversion to pharmacy channel compared to smaller competitors [23] Financial Projections - Growth Expectations: Projecting 10%-11% growth in pumps shipped, with over half expected to come from renewals [57][58] - Cost Structure: Anticipated gross margins of 65% and operating margins of 25% as the business model shifts [132] Future Product Pipeline - Mobi Tubeless: Expected to be a game changer with extended wear capabilities and improved user experience [97][100] - Closed Loop Algorithm: Development of a fully closed loop system, with clinical studies planned for 2026 [108][109] Challenges and Considerations - Patient Transition: Educating existing patients on the new pharmacy model and ensuring they understand the benefits [41][49] - Contracting Process: Building relationships with pharmacy benefit managers (PBMs) and navigating the contracting landscape [86][90] Conclusion - Tandem Diabetes Care is positioned for significant growth through innovative product offerings and a strategic shift to a pharmacy-based model, with expectations of improved profitability and market share in the diabetes care industry [132]